| Literature DB >> 27774313 |
Christiana Aryee1, William K B A Owiredu2, James Osei-Yeboah3, Ellis Owusu-Dabo4, Edwin F Laing2, Isaac K Owusu5.
Abstract
The surge in prevalence of chronic noncommunicable diseases like hypertension and chronic kidney disease has been linked with modifiable lifestyle practices and increased body fat. This study sought to compare the association between different modifiable lifestyle practices, adiposity indices, renal function parameters, and hypertension as well as the predictive implications for levels of these parameters in target cardiac organ damage among an urban Ghanaian hypertensive population. Using a hospital-based case-control study design, 241 Ghanaian indigenes from the Kumasi metropolis were recruited for this study. The case group was made up of 180 hypertensives and 61 normotensives served as controls. In addition to sociodemographic data, standard haemodynamic, anthropometric, renal function, and cardiac organ damage assessments were done. The prevalence of chronic kidney disease (CKD) ranged from 13.3% to 16.6% depending on the equation used in estimating the glomerular filtration rate (eGFR). Percentage cluster distribution by chronic kidney disease was observed to be significantly tilted toward the upper quartiles (3rd and 4th) of the haemodynamic parameters measured. Chronic kidney disease was significantly higher among self-reported smokers and alcoholic hypertensives. In this urban population, adiposity was associated with hypertension and renal insufficiency. Chronic kidney disease was associated with hypertension and cardiac abnormalities.Entities:
Year: 2016 PMID: 27774313 PMCID: PMC5059654 DOI: 10.1155/2016/6598921
Source DB: PubMed Journal: Int J Hypertens Impact factor: 2.420
Estimates of the prevalence of CKD in the study population using the renal function equations.
| Parameter | 4v-MDRD | CG | CKD-EPI | ||||||
|
| |||||||||
| eGFR (mL/min/1.73 m2) | Total | Control | Case | Total | Control | Case | Total | Control | Case |
|
| |||||||||
| Stage 1 (≥90) | 120 (49.80) | 57 (93.40) | 63 (35.00) | 136 (56.40) | 57 (93.40) | 79 (43.90) | 117 (48.50) | 59 (96.70) | 58 (32.20) |
| Stage 2 (60 to 89) | 89 (36.90) | 4 (6.60) | 85 (47.20) | 65 (27.00) | 4 (6.60) | 61 (33.90) | 89 (36.90) | 2 (3.30) | 87 (48.30) |
| Stage 3 (30 to 59) | 32 (13.30) | 0 (0.00) | 32 (17.80) | 39 (16.20) | 0 (0.00) | 39 (21.70) | 35 (14.50) | 0 (0.00) | 35 (14.50) |
| Stage 4 (15 to 29) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (0.40) | 0 (0.00) | 1 (0.60) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| Stage 5 (<15) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
|
| |||||||||
| CKD (Stages 3 + 4 + 5) | 32 (13.30) | 0 (0.00) | 32 (17.80) | 40 (16.60) | 0 (0.00) | 40 (22.22) | 35 (14.50) | 0 (0.00) | 35 (19.40) |
Data is presented as absolute values with corresponding percentage in parenthesis. 4v-MDRD: four variable modification of diet in renal disease, CG: Cockcroft-Gault, CKD-EPI: chronic kidney disease epidemiology collaboration, eGFR: estimated glomerular filtration rate, and CKD: chronic kidney disease.
Sociodemographic characteristics of the population under study stratified by hypertension and treatment status.
| Parameter | Control | HPT-naïve | HPT-therapy |
|
|---|---|---|---|---|
| Respondents | 61 (25.3) | 40 (16.6) | 140 (58.1) |
|
| Female | 45 (73.8) | 22 (55.0) | 84 (60.0) | 0.0980 |
| Male | 16 (26.2) | 18 (45.0) | 56 (40.0) | |
| Formal sector | 45 (74.2) | 10 (24.4) | 44 (31.7) | <0.0001 |
| Informal sector | 16 (25.8) | 30 (75.6) | 96 (68.3) | |
| Alcoholics | 22 (36.1) | 32 (80.0) | 76 (54.3) | <0.0001 |
| Smokers | 3 (4.9) | 9 (22.5) | 20 (14.3) | 0.0340 |
| Exercise | 36 (59.0) | 27 (67.5) | 89 (63.6) | 0.6760 |
| Positive family history | 40 (65.6) | 31 (77.5) | 104 (74.3) | 0.3330 |
| Herbal medicine intake | 33 (54.1) | 24 (60.0) | 79 (56.4) | 0.8430 |
| Nonprescribed drug intake | 36 (59.0) | 22 (55.0) | 82 (58.6) | 0.9090 |
Data is presented as figure with corresponding percentage in parenthesis. HPT-naïve: newly diagnosed hypertensive not on antihypertensive drugs; HPT-therapy: hypertensives on antihypertensives. p is significant at 0.005.
Haemodynamic, anthropometric, serum biochemical kidney profile and estimated glomerular filtration rate of the study population stratified by hypertension status.
| Parameter | Control | HPT-naïve | HPT-therapy |
|
|---|---|---|---|---|
| SBP (mmHg) | 117.38 ± 0.96 | 152.00 ± 3.27 | 155.46 ± 1.82 | <0.0001 |
| DBP (mmHg) | 73.28 ± 0.77 | 100.50 ± 1.34 | 101.46 ± 0.94 | <0.0001 |
| Pulse (BPM) | 51.41 ± 0.91 | 76.85 ± 2.20 | 81.74 ± 1.77 | <0.0001 |
| MAP (mmHg) | 87.98 ± 0.63 | 117.67 ± 1.81 | 119.46 ± 1.01 | <0.0001 |
| WC (cm) | 69.10 ± 1.57 | 97.65 ± 2.80 | 95.69 ± 1.58 | <0.0001 |
| HC (cm) | 71.82 ± 1.56 | 102.20 ± 3.20 | 101.42 ± 2.12 | <0.0001 |
| BMI (Kg/m2) | 29.36 ± 0.65 | 29.80 ± 0.71a | 29.52 ± 0.39a | 0.9018 |
| WHR | 0.96 ± 0.01 | 0.97 ± 0.01a | 0.97 ± 0.0a | 0.9356 |
| WHtR | 0.45 ± 0.01 | 0.60 ± 0.11 | 0.59 ± 0.13 | <0.0001 |
| AVI | 9.86 ± 0.45 | 19.74 ± 1.16 | 19.09 ± 0.66 | <0.0001 |
| Conicity index | 0.929 ± 0.11 | 1.28 ± 0.04 | 1.25 ± 0.02 | <0.0001 |
| BAI | 19.49 ± 0.90 | 31.14 ± 1.60 | 31.40 ± 1.17 | <0.0001 |
| Potassium (mmol/L) | 3.20 ± 1.03 | 3.76 ± 1.05 | 3.82 ± 1.03 | 0.0001 |
| Sodium (mmol/L) | 134.89 ± 1.35 | 139.43 ± 3.20 | 146.86 ± 2.39 | <0.0001 |
| Chloride (mmol/L) | 94.89 ± 1.35 | 106.13 ± 1.12 | 112.73 ± 1.03 | <0.0001 |
| Urea (mmol/L) | 3.71 ± 0.09 | 5.66 ± 0.31 | 5.77 ± 0.14 | <0.0001 |
| Creatinine ( | 69.08 ± 1.48 | 86.81 ± 4.29 | 91.71 ± 2.38 | <0.0001 |
| Uric acid ( | 125.68 ± 1.02 | 157.19 ± 1.07 | 176.66 ± 1.05 | <0.0001 |
| Microalbuminuria (mg) | 4.52 ± 1.14 | 5.60 ± 1.21a | 7.38 ± 1.12 | 0.0336 |
| 4v-MDRD (mL/min/1.73 m2) | 127.63 ± 1.03 | 101.78 ± 1.13a | 87.05 ± 1.06 | 0.0002 |
| CG (mL/min/1.73 m2) | 130.24 ± 1.03 | 103.26 ± 1.12a | 82.61 ± 1.05 | <0.0001 |
| CKD-EPI (mL/min/1.73 m2) | 131.23 ± 1.03 | 90.33 ± 1.06 | 81.49 ± 1.05 | <0.0001 |
Data is presented as mean ± standard error of the mean. HPT-naïve: newly diagnosed hypertensive not on antihypertensive drugs, HPT-therapy: hypertensives on antihypertensives, SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean arterial pressure, WC: waist circumference, HC: hip circumference, BMI: body mass index, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, AVI: abdominal volume index, BAI: body adiposity index, 4v-MDRD: four-variable modification of diet in renal disease, CG: Cockcroft-Gault, CKD-EPI: chronic kidney disease epidemiology collaboration. Bonferroni post hoca: no statistically significant difference compared with control.
Partial correlation coefficients of haemodynamic parameters, anthropometric variables, and biochemical kidney markers of study population (upper right sided) and indices of hypertension group (lower left sided), adjusted for age and gender.
| Index | SBP | DBP | Pulse | MAP | WC | HC | BMI | WHR | WHtR | CI | AVI | BAI | K+ | Na+ | CL− | Urea | Creat | UA | MA | MDRD | CG | EPI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP | .51 | .20 | .85 | .20 | .16 | −0.03 | 0.04 | .19 | .24 | .18 | .30 | 0.07 | .23 | .39 | .21 | .15 | 0.10 | −0.09 | −0.03 | −0.01 | −0.06 | |
| DBP | .39 | .25 | .89 | .19 | .19 | 0.05 | 0.00 | 0.12 | .17 | .16 | .28 | 0.01 | .35 | .52 | 0.11 | .13 | 0.01 | 0.01 | 0.00 | 0.08 | −0.02 | |
| Pulse | 0.02 | 0.01 | .26 | .64 | .69 | .17 | 0.07 | .58 | .57 | .68 | .66 | .22 | .20 | .40 | .22 | 0.05 | .29 | 0.01 | −0.01 | 0.11 | −0.01 | |
| MAP | .83 | .83 | 0.02 | .22 | .20 | 0.01 | 0.02 | .18 | .24 | .19 | .31 | 0.04 | .33 | .53 | .18 | .16 | 0.06 | −0.04 | −0.01 | 0.04 | −0.05 | |
| WC | 0.04 | −0.07 | .60 | −0.02 | .95 | .37 | 0.1 | .93 | .89 | .99 | .86 | .19 | .14 | .40 | .29 | .21 | .44 | 0.08 | −.18 | 0.03 | −.20 | |
| HC | 0.02 | −0.04 | .66 | −0.01 | .94 | .33 | −0.12 | .88 | .84 | .96 | .90 | .23 | .13 | .35 | .26 | .21 | .47 | 0.06 | −.21 | −0.01 | −.21 | |
| BMI | −0.06 | 0.01 | .18 | −0.03 | .37 | .32 | 0.03 | .47 | −0.03 | .33 | .43 | 0.02 | 0.00 | 0.09 | 0.01 | 0.06 | −0.03 | 0.12 | −0.11 | .19 | −0.10 | |
| WHR | 0.04 | −0.02 | 0.08 | 0.01 | 0.07 | −.16 | 0.00 | 0.10 | 0.10 | 0.09 | −0.10 | −0.04 | 0.00 | 0.03 | 0.07 | −0.08 | −0.09 | 0.01 | .17 | .18 | 0.09 | |
| WHtR | 0.07 | −0.09 | .55 | −0.01 | .93 | .86 | .42 | 0.07 | .80 | .92 | .95 | .16 | 0.12 | .33 | .29 | .20 | .43 | 0.1 | −.21 | −0.04 | −.22 | |
| CI | 0.10 | −0.08 | .51 | 0.01 | .87 | .81 | −0.09 | 0.08 | .80 | .89 | .75 | .16 | .15 | .37 | .29 | .19 | .49 | 0.05 | −.16 | −0.1 | −.18 | |
| AVI | 0.04 | −0.07 | .65 | −0.02 | .99 | .96 | .33 | 0.07 | .92 | .87 | .88 | .21 | 0.11 | .36 | .29 | .20 | .46 | 0.07 | −.18 | 0.01 | −.20 | |
| BAI | 0.05 | −0.07 | .60 | −0.01 | .86 | .89 | .39 | −0.13 | .95 | .73 | .87 | .24 | .25 | .40 | .35 | .27 | .52 | 0.11 | −.30 | −.14 | −.32 | |
| K+ | 0.02 | −0.10 | .21 | −0.05 | .20 | .24 | 0.09 | −0.05 | .19 | .15 | .22 | .21 | .21 | 0.11 | .20 | .16 | .19 | −0.03 | −.14 | −0.1 | −0.11 | |
| Na+ | 0.06 | .16 | 0.04 | 0.14 | −0.06 | −0.04 | −0.04 | −0.02 | −0.04 | 0.04 | 0.06 | −0.02 | .20 | .35 | .16 | 0.10 | −0.03 | −0.02 | 0.08 | 0.11 | 0.02 | |
| CL− | 0.12 | 0.10 | 0.09 | 0.13 | 0.14 | 0.11 | 0.04 | 0.06 | 0.10 | 0.12 | .16 | 0.06 | 0.03 | 0.03 | .31 | .18 | .21 | 0.08 | −0.04 | 0.08 | −0.08 | |
| Urea | 0.09 | −0.12 | 0.08 | −0.02 | .20 | .17 | 0.00 | 0.09 | .22 | .19 | .21 | .20 | .18 | 0.04 | 0.02 | .38 | .29 | −0.05 | −.23 | −.18 | −.27 | |
| Creat | 0.09 | 0.04 | −0.03 | 0.08 | .17 | .17 | 0.07 | −0.11 | .17 | 0.14 | .16 | .17 | 0.15 | 0.05 | 0.06 | .36 | .30 | 0.02 | −.80 | −.73 | −.79 | |
| UA | 0.02 | −0.14 | .24 | −0.07 | .45 | .46 | −0.06 | −0.13 | .43 | .49 | .45 | .42 | .18 | −0.12 | 0.11 | .24 | .27 | 0.02 | −.29 | −.27 | −.27 | |
| MA | −0.13 | −0.06 | −0.04 | −0.11 | 0.02 | 0.00 | 0.10 | 0.04 | 0.05 | 0.00 | 0.02 | 0.03 | −0.04 | −0.08 | 0.09 | −0.09 | 0.03 | 0.03 | −0.05 | −0.03 | −0.05 | |
| MDRD | −0.02 | 0.04 | 0.01 | 0.01 | −.20 | −.22 | −0.13 | 0.21 | −.22 | −.16 | −.19 | −.24 | −.15 | 0.10 | 0.00 | −.23 | −.81 | −.29 | −0.06 | .92 | .90 | |
| CG | −0.05 | 0.05 | 0.08 | −0.01 | −0.06 | −0.09 | .15 | 0.20 | −0.12 | −.19 | −0.06 | −.16 | −0.12 | 0.07 | 0.04 | −.23 | −.77 | −.29 | −0.07 | .94 | .81 | |
| EPI | −0.03 | 0.05 | 0.04 | 0.01 | −.20 | −.21 | −0.13 | 0.11 | −.22 | −.17 | −.19 | −.22 | −0.12 | 0.05 | −0.01 | −.26 | −.80 | −.26 | −0.06 | .90 | .83 |
SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean arterial pressure, WC: waist circumference, HC: hip circumference, BMI: body mass index, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, CI: conicity index, AVI: abdominal volume index, K+: potassium, Na+: sodium, CL−: chloride, creat: creatinine, UA: uric acid, MA: microalbumin, MDRD: four-variable modification of diet in renal disease, CG: Cockcroft-Gault, and EPI: chronic kidney disease epidemiology collaboration. Correlation is significant at 0.05 and correlation is significant at 0.01.
Figure 1Estimates of the prevalence of CKD in the study population using the renal function equations stratified by therapy and gender. N: drug naïve, T: therapy, F: female, and M: male.
Figure 2Estimates of the prevalence of CKD in the study population using the renal function equations stratified by alcohol consumption and smoking status. NA: nonalcoholic, A: alcoholic, S: smoker, and NS: nonsmoker.
Figure 3Renal insufficiency quartile cluster distributions with haemodynamic parameters. SBP: systolic blood pressure, DBP: diastolic blood pressure, Q-1: first quartile, Q-2: second quartile, Q-3: third quartile, and Q-4: fourth quartile. p value for linear by linear association is significant at 0.05 for two tail.
Figure 4Prevalence of microalbuminuria among hypertension subjects stratified by sociodemographic characteristics. MA: microalbuminuria. (a) Alcohol intake, (b) smoking status, (c) herbal medicine intake, and (d) physical activity level.
Staged renal insufficiency stratified by the presence of clinical manifestation of cardiac disorder (nonspecific sinuses, left ventricular hypertrophy, and heart enlargement).
| Parameter | Equation | Condition | Stage 1 | Stage 2 | Stage 3 | Stage 4 |
|
|---|---|---|---|---|---|---|---|
| Left ventricular hypertrophy (electrocardiograph) | 4v-MDRD |
| 66 (74.12) | 17 (19.10) | 6 (6.74) | 0 (0.00) |
|
|
| 54 (35.53) | 72 (47.37) | 26 (17.11) | 0 (0.00) | |||
| CG |
| 68 (76.40) | 12 (13.48) | 9 (10.11) | 0 (0.00) |
| |
|
| 68 (44.74) | 53 (34.87) | 30 (19.74) | 1 (0.67) | |||
| CKD-EPI |
| 66 (74.16) | 17 (19.10) | 6 (6.74) | 0 (0.00) |
| |
|
| 51 (33.55) | 72 (47.37) | 29 (19.08) | 0 (0.00) | |||
|
| |||||||
| Left ventricular hypertrophy (echocardiograph) | 4v-MDRD |
| 62 (76.54) | 16 (19.75) | 3 (3.70) | 0 (0.00) |
|
|
| 58 (36.25) | 73 (45.63) | 29 (18.13) | 0 (0.00) | |||
| CG |
| 65 (80.25) | 12 (14.83) | 4 (4.94) | 0 (0.00) |
| |
|
| 71 (44.38) | 53 (33.13) | 35 (21.88) | 1 (0.63) | |||
| CKD-EPI |
| 64 (79.00) | 14 (17.30) | 3 (3.70) | 0 (0.00) |
| |
|
| 53 (33.10) | 75 (46.90) | 32 (20.00) | 0 (0.00) | |||
|
| |||||||
| Cardiomegaly (X-ray) | 4v-MDRD |
| 74 (71.80) | 21 (20.40) | 8 (7.80) | 0 (0.00) |
|
|
| 46 (33.30) | 68 (49.30) | 24 (17.40) | 0 (0.00) | |||
| CG |
| 79 (76.70) | 18 (17.48) | 6 (5.83) | 0 (0.00) |
| |
|
| 57 (41.30) | 47 (34.06) | 33 (23.91) | 1 (0.73) | |||
| CKD-EPI |
| 64 (79.00) | 14 (17.30) | 3 (3.70) | 0 (0.00) |
| |
|
| 53 (33.10) | 75 (46.90) | 32 (20.00) | 0 (0.00) | |||
Data is presented as figure with percentage in parenthesis. 4v-MDRD: four-variable modification of diet in renal disease, CG: Cockcroft-Gault, and CKD-EPI: chronic kidney disease epidemiology collaboration equation.
Equations for chronic kidney disease epidemiology collaboration (CKD-EPI).
| Gender | Serum creatinine | Estimated glomerular equation |
|---|---|---|
| Female | ≤62 (≤0.7) |
|
| Female | >62 (>0.7) |
|
| Male | ≤80 (≤0.9) |
|
| Male | >80 (>0.9) |
|